ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Silver Sponsor

Silver Sponsor

Pharmaceutical News

  • AI-assisted approach identifies IRS4 as a promising drug target in multiple solid tumors
    on May 8, 2026 at 8:00 am

    Published in Science Advances, St. Jude Children’s Research Hospital scientists used a mix of genetic cancer dependency data, artificial intelligence (AI) and naturally occurring mutations to prioritize safer cancer drug targets. They focused their efforts on targets most likely to be effective while limiting unwanted toxicity, identifying IRS4 as a potential dependency across multiple tumor types. The work provides a proof of principle for evaluating potential toxicity early in the search for novel therapeutics.

  • Researchers identify natural compound that disarms drug-resistant bacteria
    on May 7, 2026 at 8:00 am

    Every year, antibiotic-resistant Staphylococcus aureus, commonly known as “staph,” causes serious infections and outbreaks in hospitals and community settings, disproportionately affecting vulnerable populations, including the elderly and those with weakened immune systems. Methicillin-resistant strains, known as MRSA, are a leading contributor to deaths associated with antimicrobial resistance globally.

  • Scientists discover a new way to make drug-resistant cancer treatable again
    on May 6, 2026 at 8:00 am

    Cancer cells survive by repairing damage to their DNA - even damage that would normally be fatal. One of their most important defense systems is homologous recombination, a high-precision repair pathway that fixes broken DNA using key proteins such as RAD51 and CHK1. While therapies such as PARP inhibitors have successfully targeted this vulnerability, many tumors eventually regain their DNA repair ability and become resistant to treatment.

  • A new drug concept to treat obesity and type 2 diabetes
    on May 5, 2026 at 8:00 am

    A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP signalling pathway as a “door opener” and delivers an additional metabolic modulator specifically into the target cells. In laboratory experiments, mice subsequently ate less, lost more weight and showed improved blood-glucose values compared with reference treatments.

  • Autonomous AI-based drug prescribing rife with potential problems
    on May 4, 2026 at 8:00 am

    A first-of-its-kind pilot program in Utah developed by a health-technology startup company uses artificial intelligence to automatically renew certain prescriptions for patients with chronic conditions such as hypertension and diabetes. But according to a new paper co-written by a University of Illinois Urbana-Champaign expert in legal issues surrounding cutting-edge medical technology, autonomous AI-based drug prescribing raises important clinical and legal issues.